XPH ETF: What Is It? A Complete Guide to Returns, Expense Ratio, Holdings and Alternative ETFs
The State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passive thematic product that holds U.S. pharmaceutical companies on a near equal-weight basis. Its equal-weighted structure and its differences in weighting and holdings versus PJP, IHE and PPH are the key selection criteria.
SubscribeWhat Is the State Street SPDR S&P Pharmaceuticals ETF?
It is a passive thematic ETF that holds U.S. pharmaceutical companies on a near equal-weight basis. It spreads its weight relatively evenly across large pharmaceutical companies as well as small and mid-sized ones, giving exposure to the pharmaceutical industry as a whole.
It suits investors who want exposure to a pharmaceutical sector not skewed toward large caps, and who are willing to accept new drug development outcomes, drug pricing regulation and volatility.
It is an ETF managed passively (index-tracking) by State Street.
How Does the State Street SPDR S&P Pharmaceuticals ETF Invest?
| Item | Details |
|---|---|
| Investment target | U.S. pharmaceutical companies |
| Management style | Passive (equal-weighted) |
| Theme | Pharmaceuticals |
| Dividend frequency | Quarterly dividends |
| Total expense ratio | 0.35% |
It tracks an index that holds U.S. pharmaceutical companies on a near equal-weight basis. Unlike market-cap weighting, it places relatively even weight on large pharmaceutical companies and small and mid-sized ones, which reduces concentration in large caps and gives greater exposure to the performance of smaller pharmaceutical names.
- Equal-weighted composition of pharmaceutical companies
- Even exposure that extends to small and mid-sized pharmaceutical companies
State Street SPDR S&P Pharmaceuticals ETF Size and Costs (AUM and Management Fee)
Assets under management (AUM) stand at $463.0M, and the total expense ratio (Expense Ratio) is 0.35% per year.
The main point of comparison is its equal-weighted composition versus market-cap-weighted pharmaceutical ETFs and broad healthcare ETFs.
State Street SPDR S&P Pharmaceuticals ETF Performance and Trends
1-Year Price Performance
Dividend & Yield
52-Week Price RangePharmaceutical stocks are driven by clinical trial results for new drugs, drug pricing regulation and mergers and acquisitions, and because of the equal-weighted composition, the performance of small and mid-sized pharmaceutical companies has a larger effect on the whole. With a heavier share of small and mid-sized names, volatility tends to be somewhat higher than in market-cap-weighted pharmaceutical products.
Fund flows into pharmaceutical thematic products split depending on new drug momentum, drug pricing policy and risk appetite, and demand for evenly held small and mid-sized pharmaceutical exposure can also shift money toward related products. It is also worth noting that performance varies with clinical results and the regulatory environment.
State Street SPDR S&P Pharmaceuticals ETF Pros and Cons
Equal-weighted pharmaceutical diversification is its strength, while drug pricing regulation, clinical risk and small and mid-cap volatility are points to consider.
💪 Key Strengths
⚠️ Points of Caution
State Street SPDR S&P Pharmaceuticals ETF Alternative ETFs and Related Products
For pharmaceutical exposure based on market-cap or momentum weighting, direct substitutes include PJP, and for other pharmaceutical exposure, products such as IHE are also worth comparing. To focus on global large-cap pharmaceutical companies, products such as PPH can be reviewed as well. This ETF holds U.S. pharmaceutical companies on a near equal-weight basis and gives even exposure that extends to small and mid-sized names, which is its differentiating criterion.
Peer Comparison ETFs| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
 VFH | Vanguard Financials ETF | $139.82 | +1.8% | $13.4B | 0.09% | 1.68% | +9.7% |
 ONEQ | Fidelity Nasdaq Composite Index ETF | $99.25 | -1.0% | $10.5B | 0.21% | 0.52% | +6.2% |
 VIS | Vanguard Industrials ETF | $325.48 | +1.5% | $7.7B | 0.09% | 0.94% | +8.3% |
 FV | First Trust Dorsey Wright Focus 5 ETF | $73.26 | -2.4% | $3.9B | 0.89% | 0.36% | +18.6% |
 IYF | iShares U.S. Financials ETF | $132.97 | +1.6% | $3.7B | 0.37% | 1.46% | +8.5% |
Top Holdings| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
 MYMK | State Street My2031 Municipal Bond ETF | 0.17% | $24.64 | -0.1% | $0.0M | - | 2.61% |
 DFTX | Definium Therapeutics Inc | 0.03% | $32.47 | -10.6% | $4.4B | - | - |
 MBX | MBX Biosciences Inc | 0.03% | $54.40 | -2.6% | $2.6B | - | - |
 ELVN | Enliven Therapeutics Inc | 0.02% | $44.63 | +0.9% | $3.3B | - | - |
 CORT | Corcept Therapeutics Inc | 0.02% | $80.46 | -0.8% | $8.7B | 192.2 | - |
 ALMS | Alumis Inc | 0.02% | $6.38 | -5.2% | $851.7M | - | - |
 TRVI | Trevi Therapeutics Inc | 0.02% | $13.63 | +0.5% | $1.9B | - | - |
State Street SPDR S&P Pharmaceuticals ETF Investor Checkpoints
These are the points to review before investing in XPH. Equal-weighted pharmaceutical diversification is appealing, but drug pricing regulation, clinical risk and small and mid-cap volatility need to be checked in advance. It is also a good idea to compare it with market-cap-weighted pharmaceutical and broad healthcare products.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 💊 Equal weighting | Review the weights of large and small to mid-sized pharmaceutical companies | Even exposure |
| ⚖️ Drug pricing regulation | Review drug price cut policies | Needs checking |
| ⚗️ Clinical risk | Review clinical risk of small and mid-sized pharmaceutical companies | Rather sensitive |
| ⚡ Volatility | Review volatility from small and mid-cap weighting | Somewhat high |
Drug price cut regulation and new drug clinical trial failures at small and mid-sized pharmaceutical companies are the main variables for short-term performance, and because of the equal-weighted composition, the volatility of small and mid-sized pharmaceutical companies has a larger effect on the whole. Given its concentration in a single pharmaceutical theme, it is sensitive to regulatory and clinical news.
It is a suitable candidate for investors who want to invest in a pharmaceutical sector not skewed toward large caps. If you want market-cap or momentum-weighted pharmaceutical exposure, a product such as PJP is an option, and if you want equal-weighted pharmaceutical exposure, it is advisable to compare this product alongside it before choosing.
SubscribeDisclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 10, 2026.
Today's 5 AI picks, all free